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Objective: To assess the influence of body-mass index (BMI) on the association of ankle-brachial index
(ABI) with mortality.
Patients and Methods: We conducted a prospective study of National Health and Nutrition Examination
Survey participants enrolled from January 1, 1999 to December 31, 2002 with BMI and ABI data available.
ABI categories were <0.9 (low), 0.9 to 1.3 (reference), and >1.3 (high). BMI categories were <30 kg/m2
(nonobese) and 30 kg/m2 (obese). Cardiovascular (CV) and all-cause mortality were assessed by Na-
tional Death Index records. Cox proportional-hazards models and Kaplan-Meier survival estimates were
used to compare groups.
Results: In total, 4614 subjects were included, with mean age 5612 years and BMI 286 kg/m2.
Median follow-up was 10.3 years (interquartile range [IQR]: 9.3 to 11.4 years). Low and high ABI were
present in 7% and 8%, respectively. After adjustment, low ABI was associated with increased all-cause and
CV mortality in nonobese (hazard ratio [HR] 1.5, 95% CI, 1.1-2.1 for all-cause and 3.0 [1.8-5.1] for CV
mortality) and obese individuals (1.8 [1.2-2.7] and 2.5 [1.2-5.6], respectively) compared with reference.
High ABI was associated with increased CV mortality in nonobese (2.2 [1.1-4.5]) but not obese patients; it
was not associated with all-cause mortality overall or when stratified by BMI.
Conclusion: In a US cohort, weight influenced the prognostic significance of high ABI. This may be
related to technical factors reducing compressibility of the calf arteries in obese persons compared with
those who are nonobese.
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Center, MO (D.P.).L ow ankle brachial index (ABI) has beenconsistently associated with increasedcardiovascular (CV) and all-cause mor-
tality in several epidemiologic studies in a
wide variety of populations.1e6 However, the
prognostic significance of a high ABI is less
clear. Various studies have yielded conflicting
results, with some showing a strong associa-
tion with CV and all-cause mortality, others
showing no association, and still others
showing an association with CV events but
not mortality.4,7e10 The reasons for these
discrepant findings are not well understood.Mayo Clin Proc Inn Qual Out n December 2019;3(4):409-417 n http
www.mcpiqojournal.org n ª 2019 Mayo Foundation for Medical Ed
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-One hypothesis is that obesity may itself
contribute to a high ABI measurement and
thus influence the prognostic significance of
ABI in obese individuals.11,12 However, the
impact of BMI on the association between
abnormal ABI (either low or high ABI) and
both all-cause and CV mortality has not been
previously examined. We hypothesized that
the prognostic significance of an abnormal
ABI (especially high ABI) is significantly
affected by BMI. The objective of this study
was to examine the association of ABI with
CV and all-cause mortality according to BMIs://doi.org/10.1016/j.mayocpiqo.2019.08.006
ucation and Research. Published by Elsevier Inc. This is an open access article under
nc-nd/4.0/).
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410(in both obese and nonobese individuals) in
the general US population using the National
Health and Nutrition Examination Survey
(NHANES) sample from 1999 to 2002.
PATIENTS AND METHODS
Study Population
We used data from NHANES, which is a
cross-sectional study of US residents.13 The
NHANES design consisted of a multistage,
stratified, clustered probability dataset
providing a representative sample of the
noninstitutionalized civilian population of
the United States. The study protocol was
approved by the National Center for Health
Statistics of the Centers for Disease Control
and Prevention institutional review board. All
participants gave written informed consent
for the study. We queried the NHANES pop-
ulation database between January 1, 1999,
and December 31, 2002. All subjects with
available BMI and ABI data were included.
We excluded those with missing data on any
of the key variables outlined herein. The final
sample size for the study was 4614 subjects.
Data Collection
The methodology used for data collection by
NHANES has been described in detail else-
where.13 In brief, data including past medical
history, medication use, demographics, educa-
tion level, alcohol consumption, and smoking
status were collected using a standardized ques-
tionnaire. Using a mobile examination center, a
detailed physical examination was completed
for each participant. Blood pressure was
measured 3 times during the visit. For the
purpose of the study, hypertension was defined
as a systolic blood pressure 140 mm Hg or
diastolic blood pressure90mmHg, or receipt
of antihypertensive therapies. Diabetes mellitus
was defined as a fasting plasma glucose level
126 mg/dL, a nonfasting plasma glucose
200mg/dL, or ongoing use of oral hypoglyce-
mic agents for diabetes treatment.
The NHANES ABImeasurement protocol is
detailed elsewhere.14 In brief, the right arm
blood pressure (BP) and the posterior tibial ar-
tery BP were used to calculate the ABI. For pa-
tients whose right arm BP could not be
recorded (for various reasons listed in the
NHANES protocol), left arm BP was used.Mayo Clin Proc Inn Qual Out n December 2019The size of the arm cuff was based on the arm
circumference, with a larger cuff used for larger
circumference. The lower extremity cuff used
for each patient was the same size as that used
for his or her upper arm. Thus, the study
accounted for patient size in choosing the
cuff. Categories for ABI were defined as <0.9
(low), 0.9 to 1.3 (normal, reference range),
and >1.3 (high). Height and weight were
measured, and BMI was calculated as weight
in kilograms divided by height in meters
squared. BMI categories were<30 kg/m2 (non-
obese) and 30 kg/m2 (obese).
For the purposes of our investigation, a
single measurement of ABI, as obtained in
the NHANES cohort, was thought to be
adequate for analysis, given that several previ-
ous epidemiologic studies have used single
ABI measurements to predict CV outcomes
with consistent results.15e17 The inter- and
intraobserver variability of ABI measurements
has been shown to be quite small, especially
in relatively healthy populations such as the
NHANES cohort.18e23 The factor that may
most significantly affect the accuracy of ABI
measurements is use of an appropriately sized
cuff, which was well standardized in the
NHANES protocol.
Outcomes
All participants were followed up from their en-
try into the NHANES study (baseline) to
December 31, 2011. Outcomes assessed for
this studywere all-cause and CVmortality. Vital
status and assignment of cause of death were
based upon probabilistic matching of NHANES
data with National Death Index records. CV
mortality was defined based on reported cause
of death on death certificate records. For deaths
between 1988 through 1998, International
Classification of Diseases, 10th Revision (ICD-
10) was used (ICD-10 codes I00-I99), as has
been used in previous studies fromNHANES.13
Statistical Analysis
Sampling weights were used to account for the
complex survey design. Descriptive statistics
were reported as mean and standard deviation
for continuous variables and percentages for
categorical variables. Baseline characteristics
were compared using analysis of variance
(ANOVA) and c2 tests in pairwise analyses
when appropriate. We presented 10-year;3(4):409-417 n https://doi.org/10.1016/j.mayocpiqo.2019.08.006
www.mcpiqojournal.org
BMI IMPACT ON ABI-MORTALITY ASSOCIATIONpredicted incidence rates, adjusted for demo-
graphic characteristics and CV risk factors,
for all-cause and CV mortality for each ABI
category in both obese and nonobese partici-
pants. Kaplan-Meier survival curves were pre-
sented for the outcome of interest for each
category of ABI according to BMI. Cox propor-
tional hazards models were used to estimate
hazards ratios (HRs) for mortality. We used
2 different models with Model 1 adjusting
for age, race, gender, income (<$20,000 vs
$20,000), and education (<12 years vs
>12 years) and Model 2 further adjusting for
history of diabetes, systolic blood pressure,
total cholesterol, HDL cholesterol, history of
CV disease, and current smoking. Interaction
between ABI and BMI for all-cause and CV
mortality was examined from the fully
adjusted model using the Wald test. We
used continuous net reclassification index to
test if risk stratification for all-cause and CV
mortality improved with the addition of ABI
to conventional CV risk factors for both obese
and nonobese individuals. P values <.05 were
considered statistically significant. All statisti-
cal analyses were done using STATA 12 (Stata-
Corp, College Station, TX).
RESULTS
The study cohort was composed of 4614 sub-
jects, among whom 52% were female. Mean
age was 5612 years. Subjects were followed
up for a median period of 10.3 years (IQR: 9.3
to 11.4 years) from enrollment. Baseline charac-
teristics of the study population by ABI and BMI
are displayed inTable 1. Seven percent (n¼325)
had low ABI (<0.9), whereas 8% (n¼358) had
high ABI (>1.3). The population was predom-
inantly white (n¼3583, 78%), and 52% were
women. In the nonobese group, there were sig-
nificant differences in age (P<.001), female sex
(P<.001), and the percentage of white subjects
(P¼.03). Similar findings were seen in nonob-
ese patients with respect to education, house-
hold income, smoking status, systolic blood
pressure, and prevalent CV disease (P<.001
for all). In obese subjects, significant differences
in baseline characteristics were also observed
for age, female sex, percentage ofwhite subjects,
education, income, and prevalent CV disease.
Obese subjects demonstrated differences in
prevalence of diabetes (P¼.01), as well as total
cholesterol andHDL cholesterol concentrationsMayo Clin Proc Inn Qual Out n December 2019;3(4):409-417 n http
www.mcpiqojournal.org(P<.001), which were not observed in the non-
obese subjects. Finally, in contrast to the non-
obese group, obese subjects did not have
significant differences in smoking status
(P¼.4) or systolic blood pressure (P¼.1) be-
tween ABI groups. Other factorsdsuch as level
of education, household income, blood pres-
sure, diabetes, and incident CV diseasedwere
not significantly different at baseline among
the ABI groups, regardless of obesity status.
To assess the outcomes of all-cause and CV
mortality in subjects stratified by ABI and BMI,
survival curves were constructed using the
Kaplan-Meier method, as depicted in the
Figure (A and B, respectively). A significantly
lower probability of survival from all-cause
mortality was observed for low ABI subjects
with both normal and high BMI, compared
with all other groups (log rank test P<.001).
This survival difference was detectable at 2
years, and its magnitude continued to increase
throughout the duration of follow-up. Similar
trends were seen for survival from cardiovascu-
lar mortality (Figure [B]), with worse survival in
the low ABI groups for both normal and high
BMI (P<.001).
The association of ABI with risk of
all-cause and cardiovascular mortality strati-
fied by BMI is presented in Table 2. After
adjustment for demographic variables and
traditional cardiovascular risk factors, low
ABI was associated with increased risk of
all-cause and cardiovascular mortality in both
normal BMI (HR 1.5, 95% confidence interval
[CI], 1.1-2.1 for all cause and 3.0 (1.8-5.1) for
cardiovascular mortality) and high BMI 1.8
(1.2-2.7) for all-cause and 2.5 (1.2-5.6) for
cardiovascular mortality) compared with those
with ABI 0.9-1.3. We also observed that those
with high ABI had a higher risk of cardiovas-
cular mortality compared with ABI 0.9-1.3 in
the nonobese individuals (2.2 [1.1-4.5]) but
not in the obese group (0.6 [0.2-1.7]). High
ABI was not associated with all-cause mortality
when stratified by body mass. Adjusted inci-
dence rates for all-cause and cardiovascular
mortality according to ABI and BMI are shown
in Table 3 to convey absolute risk.
We found no significant multiplicative
interaction between ABI and BMI for
either all-cause or cardiovascular mortality
(P¼.8 and P¼.09 for all-cause and cardiovas-
cular mortality, respectively). In our risks://doi.org/10.1016/j.mayocpiqo.2019.08.006 411




BMI  30 kg/m2
PABI <0.9 ABI 0.9 to 1.3 ABI >1.3 ABI <0.9 ABI 0.9 to 1.3 ABI >1.3
n 4,614 232 2653 227 NA 93 1278 131 NA
Age 56 (12) 69 (14) 55 (12) 55 (12) <.001 64 (14) 55 (11) 55 (11) <.001
Female % 2380 (52) 52 54 33 <.001 55 64 40 .01
White % 3583 (78) 80 77 85 .03 77 76 77 .01
African Americans % 404 (9) 11 8 3 18 11 5
Mexican Americans % 208 (5) 3 4 6 3 5 2
Hispanics % 240 (5) 5 6 3 2 5 2
Education 12 years % 3641 (79) 64 80 84 <.001 63 78 80 .02
Income $20,000 % 3829 (83) 67 84 90 <.001 70 81 88 .02
Current smoker % 962 (21) 34 23 9 <.001 21 17 12 .4
Diabetes % 692 (15) 18 12 10 .08 42 21 20 .01
Systolic BP mm Hg 127 (19) 141 (28) 126 (19) 121 (17) <.001 137 (27) 130 (18) 125 (15) .1
Prevalent cardiovascular disease % 508 (11) 28 9 9 <.001 30 12 16 .006
Cholesterol mg/dL 212 (41) 216 (51) 212 (41) 205 (35) .08 198 (41) 214 (41) 202 (34) <.001
HDL cholesterol mg/dL 52 (16) 54 (21) 55 (17) 53 (14) .26 49 (16) 47 (13) 47 (11) <.001
BMI (kg/m2) 28 (6) 25 (4) 25 (3) 25 (3) .07 35 (6) 35 (4) 35 (5) .8
Continuous variables reported as mean (standard deviation), whereas categorical variables are reported as n (%) in the overall sample column and percentages in subsequent
columns with corresponding n values included in the first row.
P values were computed using ANOVA or c2 tests where indicated. Values <.05 were considered statistically significant.
ABI ¼ ankle-brachial index; BMI ¼ body mass index; HDL ¼ high density lipoprotein; BP ¼ blood pressure.
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412prediction analysis, we found that risk predic-
tion for both all-cause and cardiovascular mor-
tality improved significantly when BMI was
added to the fully adjusted model with ABI
for both obese and nonobese individuals
(P<.05).
DISCUSSION
This study provides a comprehensive exami-
nation of the influence of BMI on the associa-
tion of ABI and both all-cause and
cardiovascular mortality in a nationally repre-
sentative sample of United States residents. A
key finding of the study is that high ABI
(>1.3) was not associated with an increased
risk of all-cause mortality irrespective of BMI,
although a high ABI was associated with
increased risk of cardiovascular mortality in
nonobese but not obese individuals (there
was no association in the overall group, how-
ever). The study also found that low ABI is
associated with a significantly increased risk
of both all-cause and cardiovascular mortality
in both obese and nonobese individuals.
A number of large-scale epidemiologic
studies have previously associated low ABIMayo Clin Proc Inn Qual Out n December 2019with adverse cardiovascular outcomes and
mortality.4,7,16,17,24 In a meta-analysis
including 44,590 patients from 11 epidemio-
logic studies representing 6 national popula-
tions, Heald et al.1 found that ABI <0.9
conferred a higher risk of both all-cause mor-
tality (pooled risk ratio [RR] 1.60, 95% CI,
1.32-1.95) and CV mortality (pooled RR
1.96, 95% CI, 1.46-2.64) after adjustment
for conventional cardiovascular risk factors.
Althoughmany of the cited studies adjusted
for BMI when estimating the association be-
tween ABI and their outcomes of interest, the
risk conferred by abnormal ABI stratified by
BMI has not been previously examined, to our
knowledge. Despite thewell-known association
of obesity with all-cause mortality,25,26 the val-
idity of ABI-based risk assessment in an obese
population is less clear. We found that low
ABI was associated with a similarly elevated
risk of all-cause and CV mortality in both obese
and nonobese patients.
Beyond the associations between abnormal
ABI and all-cause and CV mortality, our study
sought to examine the impact of ABI on CV














































































FIGURE. (A) Survival estimates for all-cause mortality using Kaplan-Meier
analysis. (B) Survival estimates for cardiovascular mortality using Kaplan-
Meier analysis.
BMI IMPACT ON ABI-MORTALITY ASSOCIATIONet al. found significant associations between
low ABI and cardiovascular mortality after
adjusting for the Framingham Risk Score
(FRS).2 In the Multi-Ethnic Study of Athero-
sclerosis (MESA) cohort, Criqui et al. found
the association between abnormal ABI and
CV disease events remained significant
following adjustment for other known mea-
sures of subclinical atherosclerosis.4 In the
NHANES cohort, we also found that there
was a significant improvement in risk predic-
tion for both all-cause and CV mortality
when ABI was added to the model while
adjusting for most conventional CV risk fac-
tors. This relationship remained true for both
obese and nonobese patients, a finding that
has not been clearly demonstrated previously.
The association of high ABI and CV out-
comes is less well established. Mostdalthough
not alldstudies showing an association of high
ABI with adverse outcomes have been in popu-
lations with a high underlying cardiovascular
risk. The Strong Heart Study (SHS) was among
the first to show an association between high
ABI (>1.4) and CV outcomes.7 In that study,
Resnick et al. examined 4393 American Indian
patients over an 8-year follow-up period.7 In
patients with high ABI, the relative risk ratio
was 1.77 (95%CI, 1.48-2.13) for all-causemor-
tality and 2.09 (95%CI, 1.49-2.94) for CVmor-
tality.7 SHS featured a high-risk population
with diabetes present in more than half the sub-
jects and a relatively high prevalence of high ABI
at 9.2%. Similarly, in another study of high-risk
patients on hemodialysis in Japan, Ono et al.
noted a higher risk of all-cause andCVmortality
with ABI >1.3.27 A Dutch study of 7538 pa-
tients with prevalent CV disease or risk factors
found that an ABI 1.4 was associated with
an increased risk of myocardial infarction.10
High ABI has traditionally been thought to
result from noncompressibility of lower ex-
tremity (LE) arteries related to medial arterial
calcification (MAC). MAC does portend a
poor prognosis in diabetic patients and in at
least 1 study in patients with type 1 diabetes,
subjects with ABI >1.3 had a higher likelihood
of having MAC on x-ray.28e30
It is likely that the association of high
ABI with adverse CV outcomes in high-risk
populations is related to MAC being an
etiologic factor in causing high ABI readings.
In these high-risk populations, theMayo Clin Proc Inn Qual Out n December 2019;3(4):409-417 n http
www.mcpiqojournal.orgrelationship of high ABI and adverse CV out-
comes is quite consistent across studies. How-
ever, in more general populations, the findings
have been discrepant. The Atherosclerosis Risk
in Communities (ARIC) investigators assessed
the clinical significance of high ABI in their
general population cohort from 4 US commu-
nities,9,31 They found high ABI was not associ-
ated with an increased CV event rate,
compared with normal ABI. In this general
population, in which the incidence of diabetes
and MAC is expected to be lower than SHS,
for example, there may be other factors that
result in high ABI. The MESA investigators
showed an independent, positive, and gradeds://doi.org/10.1016/j.mayocpiqo.2019.08.006 413
TABLE 2. Association of Ankle-Brachial Index With All-Cause and Cardiovascular Mortality According to Body
Mass Index
ABI
BMI <30 kg/m2 BMI 30 kg/m2 Overall
Model 1a Model 2b Model 1a Model 2b Model 1a Model 2b
All-Cause Mortality
0.9-1.3 Reference Reference Reference Reference Reference Reference
<0.9 1.8 (1.3-2.5) 1.5 (1.1-2.1) 2.0 (1.3-3.1) 1.8 (1.2-2.7) 1.8 (1.4-2.5) 1.6 (1.2-2.1)
>1.3 0.9 (0.6-1.4) 1.1 (0.8-1.6) 1.0 (0.5-2.0) 1.1 (0.6-2.3) 1.0 (0.7-1.4) 1.1 (0.8-1.6)
Cardiovascular Mortality
0.9-1.3 Reference Reference Reference Reference Reference Reference
<0.9 3.4 (2.0-5.8) 3.0 (1.8-5.1) 3.2 (1.3-7.9) 2.5 (1.2-5.6) 3.2 (2.0-5.5) 2.9 (1.8-4.7)
>1.3 1.9 (0.9-4.1) 2.2 (1.1-4.5) 0.5 (0.2-1.4) 0.6 (0.2-1.7) 1.3 (0.7-2.6) 1.5 (0.8-2.8)
aModel 1 adjusted for age, race, gender, income (< $20,000 vs  $20,000), and education (<12 years vs 12 years).
bModel 2 further adjusted for history of diabetes, systolic blood pressure, total cholesterol, HDL cholesterol, history of cardiovascular
disease, and current smoking.
Interaction P¼.8 for all-cause and 0.09 for cardiovascular mortality.
Net reclassification index P<.05 for both all-cause and cardiovascular mortality with addition of ankle-brachial index to conventional
cardiovascular risk factors for both obese and nonobese individuals.
ABI ¼ ankle-brachial index; BMI ¼ body mass index.
















a10-year predicted incidence ra
income (< $20,000 vs  $20,0
systolic blood pressure, total ch
current smoking.
ABI ¼ ankle-brachial index; BM
MAYO CLINIC PROCEEDINGS: INNOVATIONS, QUALITY & OUTCOMES
414association with increasing obesity and preva-
lent high ABI.12 Furthermore, they found that
indicators of general obesity, such as BMI,
were a stronger predictor of high ABI than
measures of visceral adiposity. This observa-
tion is supported by previous work assessing
the relationship between LE soft tissue compo-
sition and ABI. Tabara et al. used computed
tomography to measure trunk and LE soft tis-
sue composition in relation to ABI.11 Afters for All-Cause and Cardiovascular Mortality by





67 16.7 (14.8-18.5) 2.1 (1.5-2.8)
38 24.7 (18.8-30.6) 6.2 (3.6-8.7)
10 19.4 (12.8-26.0) 4.8 (1.9-7.6)
37 16.1 (14.0-18.2) 2.9 (1.2-4.6)
11 26.2 (17.3-35.0) 6.2 (1.6-10.7)
3 18.2 (6.5-29.8) 1.7 (0.4-3.7)
tes per 100 person-years. All rates adjusted for age, race, gender,
00) and education (<12 years vs 12 years), history of diabetes,
olesterol, HDL cholesterol, history of cardiovascular disease, and
I ¼ body mass index
Mayo Clin Proc Inn Qual Out n December 2019adjustment for CV risk factors, the study
found LE muscle mass and not visceral or
femoral fat or femoral circumference was inde-
pendently associated with high ABI. The
authors hypothesized that increased LE mus-
cle mass confers resistance to compression in
LE arteries, leading to higher ABI. This could
explain the lack of association of high ABI
and CV events seen in the general risk popula-
tions such as the ARIC cohort, in which BMI
was significantly higher in the high ABI group.
Furthermore, it has been shown that for the
same BMI, racial and ethnic differences exist in
body fat and muscle content. This has been
observed in comparisons of several ethnicities
including European, African, and Asian
populations.32e34 These differences in BMI
and body fat/mass content and distribution
maydto some degreedexplain differences in
various population-based studies examining
outcomes with high ABI. The MESA study
showed high ABI was associated with elevated
CV risk in persons free of known CV disease.4
The high ABI group was significantly different
from the normal ABI group in terms of BMI
(30.1 vs 28.3 kg/m2) and ethnic distribution
(Caucasians 48.2% vs 38.2%, Chinese 2.7%
vs 12.7%). It is possible that these factors also
exert influence on the prognostic significance
of high ABI.;3(4):409-417 n https://doi.org/10.1016/j.mayocpiqo.2019.08.006
www.mcpiqojournal.org
BMI IMPACT ON ABI-MORTALITY ASSOCIATIONSimilar to the ARIC study, in the NHANES
cohort we founddlooking at the overall study
populationdhigh ABI (>1.3) was not associ-
ated with an increased risk of all-cause or CV
mortality. However, when stratified according
to BMI, in those with BMI < 30, a high ABI
was associated with increased CV mortality,
although not all-cause mortality. In those with
BMI  30, high ABI was not associated with
increased CV or all-cause mortality. It is likely
that, in a population with a low prevalence of
diabetes, CV disease and, by extension, a low
likelihood of MAC, high ABI measured in obese
individuals is related to poor compressibility of
the LE arteries due to such factors as LE muscle
mass, rather than arterial disease. Another issue
is that of accurate cuff sizing when measuring
ABI. Unlike the upper extremity, where there
are recommendations for appropriate cuff
sizing, no recommendations or guidelines are
available for adequate cuff sizing based on calf
circumference for the LE.6,35 In the NHANES
protocol, there is a detailed description of
cuff-sizing methodology based on BMI, and
thus cuff sizing is likely not a significant factor
to be considered when interpreting the findings
of the current study.14
Limitations
The main limitations of our study include the
potential for residual confounding not
accounted for in our analyses, particularly
with regard to associations between high ABI
and mortality for which there is a need for
further investigation to better elucidate the un-
derlying mechanisms leading to high ABI. The
NHANES data set does not include peripheral
arterial disease symptoms for consideration
with ABI measurements, a potentially useful
discriminator in determining whether high
ABI is reflective of noncompressible vessels or
artifact related to body habitus. A cutoff value
of 1.3 was used to define high ABI, based on
previous studies of the ARIC and MESA popu-
lations,9,36 although a more recent societal
guideline suggests using a value of 1.4.37 A
sensitivity analysis to assess for changes in
outcome using an ABI cutoff of 1.4 for high
ABI in our study population was not possible
because of low numbers of subjects and events
in this higher ABI group. For the ankle pressure,
only the posterior tibialis (PT) measurement was
obtained in the NHANES protocol, without anMayo Clin Proc Inn Qual Out n December 2019;3(4):409-417 n http
www.mcpiqojournal.orgassessment of the dorsalis pedis site for compar-
ison and potential incorporation into ABI calcu-
lation. Although the latter approach is
preferable, previous studies have established
the relationship between the ABI calculated
with a PT measurement only and CV out-
comes.6,17 Only a single measure of ABI and
BMI was obtained at baseline, which may have
affected the accuracy of our findings, although
considering the large cohort and multiple pa-
tient sites in NHANES, a significant impact on
the outcomes measured seems unlikely.
Furthermore, there was no serial assessment
of BMI in the NHANES data set, which would
have provided additional valuable insights
regarding the relationship between BMI, ABI,
and CV outcomes.CONCLUSIONS
In a nationally representative US cohort, obesity
significantly influenced the prognostic signifi-
cance of high ABI. High ABI is associated with
an increased risk of CV mortality in nonobese
but not in obese patients. Low ABI is associated
with an increased risk of all-cause and CV
mortality in both nonobese and obese patients.ACKNOWLEDGMENTS
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